Neurology
Huntington’s Gets Another Chance at Proof
ASCO 2026 showed how comprehensive genomic solutions are moving from research support to the practical backbone of cancer detection, profiling, monitoring and treatment matching.
CIDP Treatment Moves Beyond the IVIg Default
Tourette Care May Finally Get a New FDA Test
Dementia Is Not the End of Personhood
Narcolepsy Treatment Starts Targeting the Cause
Optic Neuritis Moves Into the Neuroprotection Race
Huntington’s Gene Therapy Moves Back Toward the FDA Door
Alzheimer’s Research Moves Beyond Amyloid
Cellular Reprogramming Enters Neuro-Ophthalmology
Alzheimer’s Agitation Moves Closer to a Phase 2 Readout
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.